Khazal Sajad, Kebriaei Partow
Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Children's Cancer Hospital, Houston, TX.
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):713-719. doi: 10.1016/j.clml.2020.06.011. Epub 2020 Jun 27.
Despite high complete remission (CR) rates, relapse remains a significant problem among subsets of patients with B acute lymphoblastic leukemia (ALL), and is associated with poor prognosis. The recent Food and Drug Administration approval of highly effective immunotherapies for B-lineage ALL (B-ALL), blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, a chimeric antigen receptor (CAR) modified T-cell therapy, targeting CD19, or CD22, have dramatically changed the therapeutic landscape for the treatment of B-ALL, resulting in high rates of deep and durable remissions. Therefore, there is now debate regarding the role of allogeneic hematopoietic cell transplantation (HCT) in this new landscape. Herein, we review these novel agents, and discuss the sequence of therapy, including allogeneic HCT in B-ALL.
尽管完全缓解（CR）率很高，但复发仍是B急性淋巴细胞白血病（ALL）患者亚组中的一个重大问题，且与预后不良相关。美国食品药品监督管理局最近批准了针对B系ALL（B-ALL）的高效免疫疗法，包括blinatumomab、inotuzumab ozogamicin以及靶向CD19或CD22的嵌合抗原受体（CAR）修饰T细胞疗法tisagenlecleucel，这些疗法极大地改变了B-ALL的治疗格局，实现了高比例的深度持久缓解。因此，在这一新格局下，关于异基因造血细胞移植（HCT）的作用存在争议。在此，我们回顾这些新型药物，并讨论治疗顺序，包括B-ALL中的异基因HCT。
